|
| Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001 |
|
https://doi.org/10.18632/oncotarget.28341
Xiaofan Li, Cristina Abrahams, Abigail Yu, Millicent Embry, Robert Henningsen, Venita DeAlmeida, Shannon Matheny, Toni Kline, Alice Yam, Ryan Stafford, Trevor Hallam, Mark Lupher, and Arturo Molina
|
| 1-13 |
|
| Candidate drugs associated with sensitivity of cancer cell lines with DLST amplification or high mRNA levels |
|
https://doi.org/10.18632/oncotarget.28342
Christina Kuhn, Myriam Boeschen, Manuel Philip, Torsten Schöneberg, Doreen Thor, and Susanne Horn
|
| 14-20 |
|
| Correction: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma |
|
https://doi.org/10.18632/oncotarget.28336
David King, Xiao Dun Li, Gilberto S. Almeida, Colin Kwok, Polly Gravells, Daniel Harrison, Saoirse Burke, Albert Hallsworth, Yann Jamin, Sally George, Simon P. Robinson, Christopher J. Lord, Evon Poon, Daniel Yeomanson, Louis Chesler, and Helen E. Bryant
|
| 21-22 |
|
| The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option |
|
https://doi.org/10.18632/oncotarget.28338
Jessica T. Gomes, Ana Márcia V. Wanzeler, Sergio M.A. Júnior, Rosa Helena F. Chaves Soares, Carolina P. de Oliveira, Emanuelle de M. Rodrigues, Bruno M. Soares, Diego D.F.A. Alcantara, Rommel M.R. Burbano, and Fabrício M. Tuji
|
| 23-39 |
|
| Intraventricular immunovirotherapy; a translational step forward |
|
https://doi.org/10.18632/oncotarget.28343
Joshua D. Bernstock, Sarah Blitz, Kyung-Don Kang, and Gregory K. Friedman
|
| 40-43 |
|
| Correction: IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells |
|
https://doi.org/10.18632/oncotarget.28344
Rehanna Mansor, Jeff Holly, Rachel Barker, Kalina Biernacka, Hanna Zielinska, Anthony Koupparis, Edward Rowe, Jon Oxley, Alex Sewell, Richard M. Martin, Athene Lane, Lucy Hackshaw-McGeagh, and Claire Perks
|
| 44-46 |
|
| To be or not to be: the role of CD56 in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.28350
Francesca Cottini, and Don Benson
|
| 47-49 |
|
| Retraction: Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met |
|
https://doi.org/10.18632/oncotarget.28329
Chengcao Sun, Ming Sang, Shujun Li, Xiaodong Sun, Cuili Yang, Yongyong Xi, Liang Wang, Feng Zhang, Yongyi Bi, Yunfeng Fu, and Dejia Li
|
| 50-50 |
|
| Permeability and driving force: why is it difficult to control glycolytic flux by blocking lactate transporters? |
|
https://doi.org/10.18632/oncotarget.28351
Wiktoria Blaszczak, and Pawel Swietach
|
| 51-52 |
|
| Correction: Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells |
|
https://doi.org/10.18632/oncotarget.28345
Fiorella Vanderhoeven, Analía Lourdes Redondo, Ana Laura Martinez, Laura María Vargas-Roig, Angel Matias Sanchez, and Marina Inés Flamini
|
| 53-53 |
|
| The role of Kras and canonical Wnt pathways for tumorigenesis of extrahepatic biliary system |
|
https://doi.org/10.18632/oncotarget.28349
Munemasa Nagao, Akihisa Fukuda, and Hiroshi Seno
|
| 54-56 |
|
| Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) |
|
https://doi.org/10.18632/oncotarget.28352
Leo I. Gordon, Reem Karmali, Jason B. Kaplan, Rakesh Popat, Howard A. Burris III, Silvia Ferrari, Sumit Madan, Manish R. Patel, Giuseppe Gritti, Dima El-Sharkawi, F. Ian Chau, John Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan P. Iyer, William Townsend, Harry Miao, Igor Proscurshim, Shining Wang, Shilpi Katyayan, Ying Yuan, Jiaxi Zhu, Kate Stumpo, Yaping Shou, Cecilia Carpio, and Francesc Bosch
|
| 57-70 |
|
| Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer |
|
https://doi.org/10.18632/oncotarget.28353
Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Hikota Hayashi, Yohei Sasaki, Koki Kawakami, Ryoji Hyakudomi, Tetsu Yamamoto, and Yoshitsugu Tajima
|
| 71-82 |
|
| Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6 |
|
https://doi.org/10.18632/oncotarget.28115
Nicole Golob-Schwarzl, Caroline Schweiger, Carina Koller, Stefanie Krassnig, Margit Gogg-Kamerer, Nadine Gantenbein, Anna M. Toeglhofer, Christina Wodlej, Helmut Bergler, Brigitte Pertschy, Stefan Uranitsch, Magdalena Holter, Amin El-Heliebi, Julia Fuchs, Andreas Punschart, Philipp Stiegler, Marlen Keil, Jens Hoffmann, David Henderson, Hans Lehrach, Christoph Reinhard, Christian Regenbrecht, Rudolf Schicho, Peter Fickert, Sigurd Lax, and Johannes Haybaeck
|
| 83-84 |
|
| Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC) |
|
https://doi.org/10.18632/oncotarget.28355
Md Maksudul Alam, Janmaris Marin Fermin, Mark Knackstedt, Mackenzie J. Noonan, Taylor Powell, Landon Goodreau, Emily K. Daniel, Xiaohua Rong, Tara Moore-Medlin, Alok R. Khandelwal, and Cherie-Ann O. Nathan
|
| 85-95 |
|
| The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy |
|
https://doi.org/10.18632/oncotarget.28354
Anqi Shao, and David M. Owens
|
| 96-103 |
|
| Correction: KHSRP-bound small nucleolar RNAs associate with promotion of cell invasiveness and metastasis of pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.28361
Keisuke Taniuchi, and Mitsunari Ogasawara
|
| 104-104 |
|
| WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go? |
|
https://doi.org/10.18632/oncotarget.28360
Shakthivel Mani, Abhishek Chatterjee, Archya Dasgupta, Neelam Shirsat, Sridhar Epari, Girish Chinnaswamy, and Tejpal Gupta
|
| 105-110 |
|
| The “extreme phenotype approach” applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles |
|
https://doi.org/10.18632/oncotarget.28358
Martin Chevarin, Diana Alcantara, Juliette Albuisson, Marie-Agnès Collonge-Rame, Céline Populaire, Zohair Selmani, Amandine Baurand, Caroline Sawka, Geoffrey Bertolone, Patrick Callier, Yannis Duffourd, Philippe Jonveaux, Yves-Jean Bignon, Isabelle Coupier, François Cornelis, Christophe Cordier, Monique Mozelle-Nivoix, Jean-Baptiste Rivière, Paul Kuentz, Christel Thauvin, Romain Boidot, François Ghiringhelli, Marc O'Driscoll, Laurence Faivre, and Sophie Nambot
|
| 111-125 |
|
| Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation |
|
https://doi.org/10.18632/oncotarget.28365
Karam Khaddour, Joshua Dowling, Jiayi Huang, Martha Council, David Chen, Lynn Cornelius, Tanner Johanns, Sonika Dahiya, and George Ansstas
|
| 126-126 |
|
| Unveiling the non-canonical functions of EZH2 in prostate cancer |
|
https://doi.org/10.18632/oncotarget.28357
Yang Yi, Yanqiang Li, Kaifu Chen, and Qi Cao
|
| 127-128 |
|
| Correction: Biological evaluation of pyrazolyl-urea and dihydro-imidazo-pyrazolyl-urea derivatives as potential anti-angiogenetic agents in the treatment of neuroblastoma |
|
https://doi.org/10.18632/oncotarget.28346
Barbara Marengo, Elda Meta, Chiara Brullo, Chiara De Ciucis, Renata Colla, Andrea Speciale, Ombretta Garbarino, Olga Bruno, and Cinzia Domenicotti
|
| 129-130 |
|
| Addendum: Prognostic significance of isochromosome 17q in hematologic malignancies |
|
https://doi.org/10.18632/oncotarget.28295
Dorota Koczkodaj, Justyna Muzyka-Kasietczuk, Sylwia Chocholska, and Monika Podhorecka
|
| 131-131 |
|
| Unlocking the potential of molecular-driven stratification for osteosarcoma treatment and prognosis |
|
https://doi.org/10.18632/oncotarget.28364
Gaël Moquin-Beaudry, Maria Eugenia Marques da Costa, Nathalie Gaspar, and Antonin Marchais
|
| 132-132 |
|
| Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability |
|
https://doi.org/10.18632/oncotarget.28359
Clark G. Wang, Malalage N. Peiris, April N. Meyer, Katelyn N. Nelson, and Daniel J. Donoghue
|
| 133-145 |
|
| Leakage? or Secretion? unconventional protein secretion in cancer |
|
https://doi.org/10.18632/oncotarget.28368
Kohji Yamada, and Kiyotsugu Yoshida
|
| 146-147 |
|
| Correction: Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells |
|
https://doi.org/10.18632/oncotarget.28251
Suthakar Ganapathy, Bo Peng, Ling Shen, Tianqi Yu, Jean Lafontant, Ping Li, Rui Xiong, Alexandros Makriyannis, and Changyan Chen
|
| 148-148 |
|
| Addendum: Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment |
|
https://doi.org/10.18632/oncotarget.28363
Gennady M. Zharinov, Oleg A. Bogomolov, Irina V. Chepurnaya, Natalia Yu. Neklasova, and Vladimir N. Anisimov
|
| 149-149 |
|
| Mitochondria engage the integrated stress response to promote tumor growth |
|
https://doi.org/10.18632/oncotarget.28372
Dillon P. Boulton, and M. Cecilia Caino
|
| 150-152 |
|
| What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types |
|
https://doi.org/10.18632/oncotarget.28367
Christian Mark Farag, Ryan Antar, Sinan Akosman, Matthew Ng, and Michael J. Whalen
|
| 153-172 |
|
| Retraction: Methylation-induced downregulation and tumor suppressive role of microRNA-29b in gastric cancer through targeting LASP1 |
|
https://doi.org/10.18632/oncotarget.28381
Hui Li, Guoqing Liu, Ke Pan, Xiongying Miao, and Yong Xie
|
| 173-173 |
|
| C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells |
|
https://doi.org/10.18632/oncotarget.28377
Karl-Heinz Klempnauer
|
| 174-177 |
|
| Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss |
|
https://doi.org/10.18632/oncotarget.28376
Maroun Bou Zerdan, Prashanth Ashok Kumar, Elio Haroun, Nimisha Srivastava, Jeffrey Ross, and Abirami Sivapiragasam
|
| 178-187 |
|
| Correction: UBE2T knockdown inhibits gastric cancer progression |
|
https://doi.org/10.18632/oncotarget.28356
Changjiang Luo, Yunyi Yao, Zeyuan Yu, Huinian Zhou, Lingyun Guo, Junqiang Zhang, Hongtai Cao, Genyuan Zhang, Yumin Li, and Zuoyi Jiao
|
| 188-189 |
|
| Proof-of-principle: targeted childhood leukemia prevention |
|
https://doi.org/10.18632/oncotarget.28371
César Cobaleda, Manuel Ramírez-Orellana, Carolina Vicente-Dueñas, Andreas Weiss, Kim E. Nichols, and Isidro Sánchez-García
|
| 190-192 |
|
| Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells |
|
https://doi.org/10.18632/oncotarget.28382
Mikhail V. Blagosklonny
|
| 193-206 |
|
| Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway |
|
https://doi.org/10.18632/oncotarget.28386
Kamrul Hasan, and Thomas J. Kipps
|
| 207-209 |
|
| Correction: Increased expression of long non-coding RNA CCEPR is associated with poor prognosis and promotes tumorigenesis in urothelial bladder carcinoma |
|
https://doi.org/10.18632/oncotarget.28347
Yonghao Zhan, Yifan Li, Bao Guan, Xiaoying Chen, Zhicong Chen, Anbang He, Shiming He, Yanqing Gong, Ding Peng, Yuchen Liu, Zhiming Cai, Xuesong Li, and Liqun Zhou
|
| 210-210 |
|
| Cancer-associated fibroblasts: challenges and opportunities |
|
https://doi.org/10.18632/oncotarget.28385
Hossein Tavana, and Gary D. Luker
|
| 211-214 |
|
| Correction: Annexin A13 promotes tumor cell invasion in vitro and is associated with metastasis in human colorectal cancer |
|
https://doi.org/10.18632/oncotarget.28247
Guozhong Jiang, Pengju Wang, Weiwei Wang, Wencai Li, Liping Dai, and Kuisheng Chen
|
| 215-215 |
|
| Therapy drives genomic evolution in metastatic cancer |
|
https://doi.org/10.18632/oncotarget.28379
Ditte S. Christensen, and Nicolai J. Birkbak
|
| 216-218 |
|
| Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior |
|
https://doi.org/10.18632/oncotarget.28388
Fang Cheng, Victor Chérouvrier Hansson, Grigorios Georgolopoulos, and Katrin Mani
|
| 219-235 |
|
| Genetic modifiers of p53: opportunities for breast cancer therapies |
|
https://doi.org/10.18632/oncotarget.28387
Prabin Dhangada Majhi, Aman Sharma, and D. Joseph Jerry
|
| 236-241 |
|
| Retraction: Overexpression of NR4A1 is associated with tumor recurrence and poor survival in non-small-cell lung carcinoma |
|
https://doi.org/10.18632/oncotarget.28396
Bing Zhu, Jian-Ru Yang, Yang Jia, Pei Zhang, Lin Shen, Xiao-Long Li, Jing Li, and Bing Wang
|
| 242-242 |
|
| Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines |
|
https://doi.org/10.18632/oncotarget.28390
Nada Tawfeeq, Jassy Mary S. Lazarte, Yonghao Jin, Matthew D. Gregory, and Nazarius S. Lamango
|
| 243-257 |
|
| Neutrophil PAD4: how does it function in cancer beyond promoting NETosis? |
|
https://doi.org/10.18632/oncotarget.28369
Laura Garcia-Gerique, and Yulia Nefedova
|
| 258-260 |
|
| Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells |
|
https://doi.org/10.18632/oncotarget.27728
Wataru Arai, Takumi Konno, Takayuki Kohno, Yuki Kodera, Mitsuhiro Tsujiwaki, Yuma Shindo, Hirofumi Chiba, Masahiro Miyajima, Yuji Sakuma, Atsushi Watanabe, and Takashi Kojima
|
| 261-275 |
|
| p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras |
|
https://doi.org/10.18632/oncotarget.28380
Munemasa Nagao, Kenta Mizukoshi, Shinnosuke Nakayama, Mio Namikawa, Yukiko Hiramatsu, Takahisa Maruno, Yuki Nakanishi, Tatsuaki Tsuruyama, Akihisa Fukuda, and Hiroshi Seno
|
| 276-279 |
|
| Correction: YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.28393
Tao Guo, Shilei Zhao, Peng Wang, Xiaoyuan Xue, Yan Zhang, Mengying Yang, Nan Li, Zhuoshi Li, Lingzhi Xu, Lei Jiang, Lei Zhao, Patrick C. Ma, Rafael Rosell, Jinxiu Li, and Chundong Gu
|
| 280-280 |
|
| Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors |
|
https://doi.org/10.18632/oncotarget.28392
Giulia Franciosa, and Jesper V. Olsen
|
| 281-283 |
|
| Crosstalk between triple negative breast cancer and microenvironment |
|
https://doi.org/10.18632/oncotarget.28397
Karly Smrekar, Artem Belyakov, and Kideok Jin
|
| 284-293 |
|
| Retraction: Significance of B10 cell in patients with thymoma complicated with myasthenia gravis |
|
https://doi.org/10.18632/oncotarget.28160
Yang Lu, Fanjie Meng, Yang Yang, Lan Li, Donghao Wang, Yuantao Cui, Shangwen Dong, and Wanhua Wang
|
| 294-294 |
|
| Tumor necroptosis promotes metastasis through modulating the interplay between tumor and host immunity |
|
https://doi.org/10.18632/oncotarget.28404
Zhaoshan Liu, Swati Choksi, and Zheng-Gang Liu
|
| 295-296 |
|
| EGFR endocytosis: more than meets the eye |
|
https://doi.org/10.18632/oncotarget.28400
Aysegul Sapmaz, and Ayse Elif Erson-Bensan
|
| 297-301 |
|
| A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850 |
|
https://doi.org/10.18632/oncotarget.28403
Kristen R. Spencer, Daniella E. Portal, Joseph Aisner, Mark N. Stein, Jyoti Malhotra, Weichung Shih, Nancy Chan, Ann W. Silk, Shridar Ganesan, Susan Goodin, Murugesan Gounder, Hongxia Lin, Jiadong Li, Robert Cerchio, Christina Marinaro, Suzie Chen, and Janice M. Mehnert
|
| 302-315 |
|
| Correction: Calcitonin receptor is required for T-antigen-induced prostate carcinogenesis |
|
https://doi.org/10.18632/oncotarget.28394
Ajay Kale, Afaf Aldahish, and Girish Shah
|
| 316-316 |
|
| The nuclear envelope and metastasis |
|
https://doi.org/10.18632/oncotarget.28375
Emily Hansen, and James M. Holaska
|
| 317-320 |
|
| Adopted neoplastic cells and the consequences of their existence |
|
https://doi.org/10.18632/oncotarget.28408
Yuri Lazebnik
|
| 321-341 |
|
| Cancer prevention with rapamycin |
|
https://doi.org/10.18632/oncotarget.28410
Mikhail V. Blagosklonny
|
| 342-350 |
|
| Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study |
|
https://doi.org/10.18632/oncotarget.28406
Ellery Altshuler, Raymond Richhart, William King, Mahmoud Aryan, Akash Mathavan, Akshay Mathavan, Keegan Hones, Daniel F. Leach III, Logan Pucci, Joshua Riklan, Pat Haley, Ilyas Sahin, Brian Ramnaraign, Sherise Rogers, Ibrahim Nassour, Steven Hughes, Thomas J. George, and Jesus Fabregas
|
| 351-357 |
|
| Crossroads: the role of biomarkers in the management of lumps in the breast |
|
https://doi.org/10.18632/oncotarget.28402
Georg F. Weber
|
| 358-362 |
|
| Retraction: LncRNA NEAT1 enhances the radio-resistance of cervical cancer via miR-193b-3p/CCND1 axis |
|
https://doi.org/10.18632/oncotarget.28416
Dongmei Han, Jianfeng Wang, and Guanghui Cheng
|
| 363-363 |
|
| The critical immune basis for differential responses to immunotherapy in primary versus metastatic pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.28373
Brian Diskin, Sarah Schwartz, and George Miller
|
| 364-365 |
|
| Differential silencing of STAT3 isoforms leads to changes in STAT3 activation |
|
https://doi.org/10.18632/oncotarget.28412
Inbal Shamir, Ilan Tsarfaty, Gidi Paret, and Yael Nevo-Caspi
|
| 366-376 |
|
| Disruption of retinol-mediated IL-6 expression in colon cancer-associated fibroblasts: new perspectives on the role of vitamin A metabolism |
|
https://doi.org/10.18632/oncotarget.28399
Romain Villéger, Marina Chulkina, Randy C. Mifflin, Don W. Powell, and Irina V. Pinchuk
|
| 377-381 |
|
| A balancing act: how whole-genome doubling and aneuploidy interact in human cancer |
|
https://doi.org/10.18632/oncotarget.28374
Kavya Prasad, and Uri Ben-David
|
| 382-383 |
|
| Systemic AL amyloidosis: current approach and future direction |
|
https://doi.org/10.18632/oncotarget.28415
Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, and Chakra P. Chaulagain
|
| 384-394 |
|
| AGO2 in T-prolymphocytic leukemia: its canonical and non-canonical deregulation and function |
|
https://doi.org/10.18632/oncotarget.28378
Till Braun, Hanna Klepzig, and Marco Herling
|
| 395-397 |
|
| Retraction: Overexpression of microRNA-132 enhances the radiosensitivity of cervical cancer cells by down-regulating Bmi-1 |
|
https://doi.org/10.18632/oncotarget.28413
Gui-Feng Liu, Shu-Hua Zhang, Xue-Feng Li, Li-Yan Cao, Zhan-Zhao Fu, and Shao-Nan Yu
|
| 398-398 |
|
| Using cancer proteomics data to identify gene candidates for therapeutic targeting |
|
https://doi.org/10.18632/oncotarget.28420
Diana Monsivais, Sydney E. Parks, Darshan S. Chandrashekar, Sooryanarayana Varambally, and Chad J. Creighton
|
| 399-412 |
|
| From the groin to the brain: a transfemoral path to blood-brain barrier opening |
|
https://doi.org/10.18632/oncotarget.28414
Thomas C. Chen, Weijun Wang, and Axel H. Schönthal
|
| 413-416 |
|
| Correction: Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migration |
|
https://doi.org/10.18632/oncotarget.28411
Ao Zhang, Masahiro Hitomi, Noah Bar-Shain, Zafardjan Dalimov, Leigh Ellis, Kiran K. Velpula, Gail C. Fraizer, Robert G. Gourdie, and Justin D. Lathia
|
| 417-418 |
|
| Targeting cellular respiration as a therapeutic strategy in glioblastoma |
|
https://doi.org/10.18632/oncotarget.28424
Enyuan Shang, Trang Thi Thu Nguyen, Mike-Andrew Westhoff, Georg Karpel-Massler, and Markus D. Siegelin
|
| 419-425 |
|
| Human LY6 gene family: potential tumor-associated antigens and biomarkers of prognosis in uterine corpus endometrial carcinoma |
|
https://doi.org/10.18632/oncotarget.28409
Luke A. Rathbun, Anthony M. Magliocco, and Anil K. Bamezai
|
| 426-437 |
|
| Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report |
|
https://doi.org/10.18632/oncotarget.28428
Mayank Rao, Meenakshi Bhattacharjee, Scott Shepard, and Sigmund Hsu
|
| 438-438 |
|
| HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.28421
Omkar Desai, and Rui Wang
|
| 439-443 |
|
| Targeting H3K27me3 loss in pediatric brain tumors - a perspective on epigenetically guided cancer therapy |
|
https://doi.org/10.18632/oncotarget.28427
Michael Goldstein
|
| 444-447 |
|
| Correction: A novel mechanism of regulation of the oncogenic transcription factor GLI3 by toll-like receptor signaling |
|
https://doi.org/10.18632/oncotarget.28430
Stephan J. Matissek, Mona Karbalivand, Weiguo Han, Ava Boutilier, Estefania Yzar-Garcia, Laura L. Kehoe, Devin Storm Gardner, Adam Hage, Krista Fleck, Vicki Jeffers, Ricardo Rajsbaum, and Sherine F. Elsawa
|
| 448-448 |
|
| Addendum: Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report |
|
https://doi.org/10.18632/oncotarget.28286
Javad Nazarian, Gary E. Mason, Cheng Ying Ho, Eshini Panditharatna, Madhuri Kambhampati, L. Gilbert Vezina, Roger J. Packer, and Eugene I. Hwang
|
| 449-449 |
|
| Development and implementation of an automated and highly accurate reporting process for NGS-based clonality testing |
|
https://doi.org/10.18632/oncotarget.28429
Sean T. Glenn, Phillip M. Galbo Jr., Jesse D. Luce, Kiersten Marie Miles, Prashant K. Singh, Manuel J. Glynias, and Carl Morrison
|
| 450-461 |
|
| The molecular dialogue between the tumor cells and fibroblasts |
|
https://doi.org/10.18632/oncotarget.28405
Ramesh Butti, and Gopal C. Kundu
|
| 462-463 |
|
| Correction: miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.28398
Xiao Wang, Shasha Liu, Ling Cao, Tengfei Zhang, Dongli Yue, Liping Wang, Yu Ping, Qianyi He, Chaoqi Zhang, Meng Wang, Xinfeng Chen, Qun Gao, Dan Wang, Zhen Zhang, Fei Wang, Li Yang, Jieyao Li, Lan Huang, Bin Zhang, and Yi Zhang
|
| 464-465 |
|
| G-protein-coupled receptor 141 mediates breast cancer proliferation and metastasis by regulating oncogenic mediators and the p-mTOR/p53 axis |
|
https://doi.org/10.18632/oncotarget.28433
Monalisa Parija, Amit K. Adhya, and Sandip K. Mishra
|
| 466-480 |
|
| Correction: Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer |
|
https://doi.org/10.18632/oncotarget.28426
Astrid Escudero-Esparza, Michael Bartoschek, Chrysostomi Gialeli, Marcin Okroj, Sioned Owen, Karin Jirström, Akira Orimo, Wen G. Jiang, Kristian Pietras, and Anna M. Blom
|
| 481-482 |
|
| GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide |
|
https://doi.org/10.18632/oncotarget.28370
Jun Ma, Ziyu Wang, Clark C. Chen, and Ming Li
|
| 483-484 |
|
| Role of creatine shuttle in colorectal cancer cells |
|
https://doi.org/10.18632/oncotarget.28436
Mayu Kita, Rina Fujiwara-Tani, Shingo Kishi, Shiori Mori, Hitoshi Ohmori, Chie Nakashima, Kei Goto, Takamitsu Sasaki, Kiyomu Fujii, Isao Kawahara, Ujjal Kumar Bhawal, Yi Luo, and Hiroki Kuniyasu
|
| 485-501 |
|
| Addendum: Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy |
|
https://doi.org/10.18632/oncotarget.28445
Stephanie A. Toll, Hung N. Tran, Jennifer Cotter, Alexander R. Judkins, Benita Tamrazi, Jaclyn A. Biegel, Girish Dhall, Nathan J. Robison, Kaaren Waters, Palak Patel, Robert Cooper, and Ashley S. Margol
|
| 502-502 |
|
| Targeting the Src N-terminal regulatory element in cancer |
|
https://doi.org/10.18632/oncotarget.28434
Betlem Mezquita, Marjorie Reyes-Farias, and Miquel Pons
|
| 503-513 |
|
| Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer |
|
https://doi.org/10.18632/oncotarget.28419
Mira Al Jaberi, Wolfgang Clough, and Samir Dalia
|
| 514-514 |
|
| Addendum: ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma |
|
https://doi.org/10.18632/oncotarget.28448
Eric I. Marks, Sahithi Pamarthy, Don Dizon, Ari Birnbaum, Evgeny Yakirevich, Howard Safran, and Benedito A. Carneiro
|
| 515-515 |
|
| Retraction: Inhibition of microRNA-218 reduces HIF-1α by targeting on Robo1 in mice aortic endothelial cells under intermittent hypoxia |
|
https://doi.org/10.18632/oncotarget.28449
Kai-Xiong Liu, Qin Chen, Gong-Ping Chen, Jian-Chai Huang, Jie-Feng Huang, Xin-Ru He, Ting Lin, and Qi-Chang Lin
|
| 516-516 |
|
| Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC) |
|
https://doi.org/10.18632/oncotarget.28444
Hazem I. Assi, Maroun Bou Zerdan, Mohammad Hodroj, Makram Khoury, Nour Sabiha Naji, Ghid Amhaz, Reine Abou Zeidane, and Fadi El Karak
|
| 517-525 |
|
| Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma |
|
https://doi.org/10.18632/oncotarget.28441
Silvia Pietrobono, and Barbara Stecca
|
| 526-527 |
|
| Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression |
|
https://doi.org/10.18632/oncotarget.28442
Mohammad Salman Akhtar, Naseem Akhter, Arshi Talat, Raed A. Alharbi, Abdulmajeed A.A. Sindi, Faisal Klufah, Hanan E. Alyahyawi, Abdulmohsen Alruwetei, Abrar Ahmad, Mazin A. Zamzami, SVS Deo, Syed Akhtar Husain, Osama A. Badi, and Mohammad Jahir Khan
|
| 528-541 |
|
| Addendum: Laser speckle flowgraphy in juxtapapillary retinal capillary hemangioblastoma: a case report on natural course and therapeutic effect |
|
https://doi.org/10.18632/oncotarget.28297
Mizuho Mitamura, Satoru Kase, Kiriko Hirooka, and Susumu Ishida
|
| 542-542 |
|
| Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment |
|
https://doi.org/10.18632/oncotarget.28447
Valentin Feichtenschlager, Yixuan James Zheng, Wilson Ho, Linan Chen, Ciara Callanan, Christopher Chen, Albert Lee, Jose Ortiz, Klemens Rappersberger, and Susana Ortiz-Urda
|
| 543-560 |
|
| A macrophage is a macrophage is a macrophage—in metastasis |
|
https://doi.org/10.18632/oncotarget.28423
Thomas T. Tapmeier
|
| 561-562 |
|
| ACSL4: biomarker, mediator and target in quadruple negative breast cancer |
|
https://doi.org/10.18632/oncotarget.28453
Marie E. Monaco
|
| 563-575 |
|
| ERβ as a mediator of estrogen signaling in inflammatory breast cancer |
|
https://doi.org/10.18632/oncotarget.28425
Harika Nagandla, and Christoforos Thomas
|
| 576-578 |
|
| Retraction: MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1 |
|
https://doi.org/10.18632/oncotarget.28446
Yang Lin, Tianmin Xu, Shunqing Zhou, and Manhua Cui
|
| 579-579 |
|
| Investigating the prevalence of pathogenic variants in Saudi Arabian patients with familial cancer using a multigene next generation sequencing panel |
|
https://doi.org/10.18632/oncotarget.28457
Musa AlHarbi, Nahla Ali Mobark, Wael Abdel Rahman AlJabarat, Hadeel ElBardis, Ebtehal AlSolme, Abdullah Bany Hamdan, Ali H. AlFakeeh, Fatimah AlMushawah, Fawz AlHarthi, Abdullah A. AlSharm, Ali Abdullah O. Balbaid, Naji AlJohani, Alicia Y. Zhou, Heather A. Robinson, Saleh A. Alqahtani, and Malak Abedalthagafi
|
| 580-594 |
|
| Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer? |
|
https://doi.org/10.18632/oncotarget.28438
Chia-Chia Liu, and Xiao-Song Wang
|
| 595-596 |
|
| LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair |
|
https://doi.org/10.18632/oncotarget.28454
Jianli Zhou, Drew Sturtevant, Cassie Love, Aditya Kulkarni, Neha Biyani, Umesh Kathad, Elizabeth Thacker, Sandeep Dave, and Kishor Bhatia
|
| 597-611 |
|
| The hope for targeting fatty acid binding proteins in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.28437
Heather Fairfield, and Michaela R. Reagan
|
| 612-613 |
|
| Targeting GITR in cancer immunotherapy – there is no perfect knowledge |
|
https://doi.org/10.18632/oncotarget.28461
Diwakar Davar, and Roberta Zappasodi
|
| 614-621 |
|
| Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer |
|
https://doi.org/10.18632/oncotarget.28458
Devalingam Mahalingam, Salih Hanni, Anthony V. Serritella, Christos Fountzilas, Joel Michalek, Brian Hernandez, John Sarantopoulos, Paromitta Datta, Ofelia Romero, Sureshkumar Mulampurath Achutan Pillai, John Kuhn, Michael Pollak, and Ian M. Thompson
|
| 622-636 |
|
| Diphenyl ditelluride anticancer activity and DNA topoisomerase I poisoning in human colon cancer HCT116 cells |
|
https://doi.org/10.18632/oncotarget.28465
André Luiz Mendes Juchem, Cristiano Trindade, Juliana Bondan da Silva, Miriana da Silva Machado, Temenouga Nikolova Guecheva, Jaqueline Cesar Rocha, Jenifer Saffi, Iuri Marques de Oliveira, João Antonio Pêgas Henriques, and Alexandre Escargueil
|
| 637-649 |
|
| Correction: iASPP overexpression is associated with clinical outcome in spinal chordoma and influences cellular proliferation, invasion, and sensitivity to cisplatin in vitro |
|
https://doi.org/10.18632/oncotarget.28395
Yunlong Ma, Bin Zhu, Xiaoguang Liu, Zhongjun Liu, Liang Jiang, Feng Wei, Miao Yu, Fengliang Wu, Hua Zhou, Nanfang Xu, Xiao Liu, Lei Yong, Yongqiang Wang, Peng Wang, Chen Liang, and Guanping He
|
| 650-652 |
|
| Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability |
|
https://doi.org/10.18632/oncotarget.28440
Shady I. Tantawy, Natalia Timofeeva, Ana Hernandez, Aloke Sarkar, and Varsha Gandhi
|
| 653-655 |
|
| Addendum: Cerebral hemorrhage due to tuberculosis meningitis: a rare case report and literature review |
|
https://doi.org/10.18632/oncotarget.28284
Hai Zou, Ke-Hua Pan, Hong-Ying Pan, Dong-Sheng Huang, and Ming-Hua Zheng
|
| 656-656 |
|
| The dark side of PLK1: Implications for cancer and genomic instability |
|
https://doi.org/10.18632/oncotarget.28456
Lilia Gheghiani, and Zheng Fu
|
| 657-659 |
|
| Deciphering the mechanisms of action of progesterone in breast cancer |
|
https://doi.org/10.18632/oncotarget.28455
Gaurav Chakravorty, Suhail Ahmad, Mukul S. Godbole, Sudeep Gupta, Rajendra A. Badwe, and Amit Dutt
|
| 660-667 |
|
| Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.28471
Eduard Teixidor, Elia Sais, Carmen Amalia Vásquez, Walter Carbajal, Alejandro Hernández, Gloria Sánchez, Angel Izquierdo, Sara Verdura, Javier A. Menéndez, and Joaquim Bosch-Barrera
|
| 668-668 |
|
| Retraction: Emerging roles and underlying molecular mechanisms of DNAJB6 in cancer |
|
https://doi.org/10.18632/oncotarget.28439
Erhong Meng, Lalita A. Shevde, and Rajeev S. Samant
|
| 669-669 |
|
| Obesity paradox and lung cancer, metformin-based therapeutic opportunity? |
|
https://doi.org/10.18632/oncotarget.28432
Pedro Barrios-Bernal, Norma Hernández-Pedro, Luis Lara-Mejía, and Oscar Arrieta
|
| 670-671 |
|
| Targeting Ras with protein engineering |
|
https://doi.org/10.18632/oncotarget.28469
Atilio Tomazini, and Julia M. Shifman
|
| 672-687 |
|
| Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin |
|
https://doi.org/10.18632/oncotarget.28467
Joel Ohana, Uziel Sandler, Orly Devary, and Yoram Devary
|
| 688-699 |
|
| Correction: Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis |
|
https://doi.org/10.18632/oncotarget.28472
Letícia F. Leal, Ana Carolina Bueno, Débora C. Gomes, Rafael Abduch, Margaret de Castro, and Sonir R. Antonini
|
| 700-700 |
|
| Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far? |
|
https://doi.org/10.18632/oncotarget.28435
Marta Vaz Batista, José Perez-Gracia, Inês Eiriz, Maria Gion, Antonio Llombart, Sofia Braga, and Javier Cortés
|
| 701-702 |
|
| Intrathoracic synovial sarcoma with BRAF V600E mutation |
|
https://doi.org/10.18632/oncotarget.28475
Ida Russo, Sabina Barresi, Pier Luigi Di Paolo, Valentina Di Ruscio, Giada Del Baldo, Annalisa Serra, Silvia Vallese, Evelina Miele, Angela Mastronuzzi, Rita Alaggio, Andrea Ferrari, and Giuseppe Maria Milano
|
| 703-708 |
|
| Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series |
|
https://doi.org/10.18632/oncotarget.28470
Mark Chang, Wolfram Samlowski, and Raul Meoz
|
| 709-718 |
|
| Multiclonality of ER expression in DCIS – Implications for clinical practice and future research |
|
https://doi.org/10.18632/oncotarget.28450
Mangesh A. Thorat
|
| 719-720 |
|
| Addendum: Systemic AL amyloidosis: current approach and future direction |
|
https://doi.org/10.18632/oncotarget.28478
Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, and Chakra P. Chaulagain
|
| 721-721 |
|
| Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin’s lymphoma models and in cells deficient in DNA damage repair |
|
https://doi.org/10.18632/oncotarget.28479
Jianli Zhou, Drew Sturtevant, Cassie Love, Aditya Kulkarni, Neha Biyani, Umesh Kathad, Elizabeth Thacker, Sandeep Dave, and Kishor Bhatia
|
| 722-722 |
|
| The uncharacterized transcript KIAA0930 confers a cachexic phenotype on cancer cells |
|
https://doi.org/10.18632/oncotarget.28476
Takahiro Yamakawa, Guoxiang Zhang, Liza Bengrine Najjar, Chun Li, and Keiichi Itakura
|
| 723-737 |
|
| Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells |
|
https://doi.org/10.18632/oncotarget.28477
Mikolaj Filon, Bing Yang, Tanaya A. Purohit, Jennifer Schehr, Anupama Singh, Marcelo Bigarella, Peter Lewis, John Denu, Joshua Lang, and David F. Jarrard
|
| 738-746 |
|
| Addendum: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss |
|
https://doi.org/10.18632/oncotarget.28481
Maroun Bou Zerdan, Prashanth Ashok Kumar, Elio Haroun, Nimisha Srivastava, Jeffrey Ross, and Abirami Sivapiragasam
|
| 747-747 |
|
| Addendum: What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types |
|
https://doi.org/10.18632/oncotarget.28485
Christian Mark Farag, Ryan Antar, Sinan Akosman, Matthew Ng, and Michael J. Whalen
|
| 748-748 |
|
| CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies |
|
https://doi.org/10.18632/oncotarget.28473
Daniel Morillo, Gala Vega, and Victor Moreno
|
| 749-752 |
|
| Addendum: Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series |
|
https://doi.org/10.18632/oncotarget.28480
Mark Chang, Wolfram Samlowski, and Raul Meoz
|
| 753-753 |
|
| Addendum: ACSL4: biomarker, mediator and target in quadruple negative breast cancer |
|
https://doi.org/10.18632/oncotarget.28482
Marie E. Monaco
|
| 754-754 |
|
| Inhibition of glutamine metabolism: acting on tumoral cells or on tumor microenvironment? |
|
https://doi.org/10.18632/oncotarget.28443
Raul Peña
|
| 755-757 |
|
| Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies |
|
https://doi.org/10.18632/oncotarget.28487
Meghali Goswami, Jeffrey Schlom, and Renee N. Donahue
|
| 758-774 |
|
| Predicting the molecular functions of regulatory genetic variants associated with cancer |
|
https://doi.org/10.18632/oncotarget.28451
Jun S. Song, and Mohith Manjunath
|
| 775-777 |
|
| Addendum: Effectiveness of radiotherapy for local control in T3N0 rectal cancer managed with total mesorectal excision: a meta-analysis |
|
https://doi.org/10.18632/oncotarget.28484
Michael Jonathan Kucharczyk, Andrew Bang, Michael C. Tjong, Stefania Papatheodorou, and Jesus C. Fabregas
|
| 778-778 |
|
| Retraction: The prognostic potential and carcinogenesis of long non-coding RNA TUG1 in human cholangiocarcinoma |
|
https://doi.org/10.18632/oncotarget.28418
Yi Xu, Kaiming Leng, Zhenglong Li, Fumin Zhang, Xiangyu Zhong, Pengcheng Kang, Xingming Jiang, and Yunfu Cui
|
| 779-779 |
|
| Subpopulations of AIB1 isoform-expressing breast cancer cells enable invasion and metastasis |
|
https://doi.org/10.18632/oncotarget.28452
Amber J. Kiliti, Ghada M. Sharif, Anton Wellstein, and Anna T. Riegel
|
| 780-781 |
|
| Correction: Interferon beta induces apoptosis in nasopharyngeal carcinoma cells via the TRAIL-signaling pathway |
|
https://doi.org/10.18632/oncotarget.28464
Anna Makowska, Lora Wahab, Till Braunschweig, Nikiforos-Ioannis Kapetanakis, Christian Vokuhl, Bernd Denecke, Lian Shen, Pierre Busson, and Udo Kontny
|
| 782-787 |
|
| Addendum: Sequencing of BRCA1/2-alterations using NGS-based technology: annotation as a challenge |
|
https://doi.org/10.18632/oncotarget.28483
Silvana Ebner, Ria Winkelmann, Saskia Martin, Jens Köllermann, Peter J. Wild, and Melanie Demes
|
| 788-788 |
|
| Analytic validation of NeXT Dx™, a comprehensive genomic profiling assay |
|
https://doi.org/10.18632/oncotarget.28490
Juan-Sebastian Saldivar, Jason Harris, Erin Ayash, Manqing Hong, Prateek Tandon, Saloni Sinha, Patricia Miranda Hebron, Erin E. Houghton, Kaleigh Thorne, Laurie J. Goodman, Conan Li, Twinkal R. Marfatia, Joshua Anderson, Massimo Morra, John Lyle, Gabor Bartha, and Richard Chen
|
| 789-806 |
|
| Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma |
|
https://doi.org/10.18632/oncotarget.28463
Kuniko Horie, and Satoshi Inoue
|
| 807-808 |
|
| Correction: MiR-129 blocks estrogen induction of NOTCH signaling activity in breast cancer stem-like cells |
|
https://doi.org/10.18632/oncotarget.28201
Guodong Xiao, Xiang Li, Gang Li, Boxiang Zhang, Chongwen Xu, Sida Qin, Ning Du, Jichang Wang, Shou-Ching Tang, Jing Zhang, Hong Ren, Ke Chen, and Xin Sun
|
| 809-809 |
|
| Addendum: Crosstalk between triple negative breast cancer and microenvironment |
|
https://doi.org/10.18632/oncotarget.28507
Karly Smrekar, Artem Belyakov, and Kideok Jin
|
| 810-810 |
|
| Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.28508
Dae Won Kim, Francisca Beato, Youngchul Kim, Alexandra F. Tassielli, Ruifan Dai, Jason W. Denbo, Pamela J. Hodul, Mokenge P. Malafa, and Jason B. Fleming
|
| 811-818 |
|
| Reassessing the risks and benefits of COVID-19 precautions in 2023 |
|
https://doi.org/10.18632/oncotarget.28468
Thomas A. Ollila, Rashida Taher, and Prashanth Moku
|
| 819-820 |
|
| Correction: Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy |
|
https://doi.org/10.18632/oncotarget.28236
Wen Yu, De-Dong Cao, Qiu-bai Li, Hui-ling Mei, Yu Hu, and Tao Guo
|
| 821-823 |
|
| Addendum: The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option |
|
https://doi.org/10.18632/oncotarget.28504
Jessica T. Gomes, Ana Márcia V. Wanzeler, Sergio M.A. Júnior, Rosa Helena F. Chaves Soares, Carolina P. de Oliveira, Emanuelle de M. Rodrigues, Bruno M. Soares, Diego D.F.A. Alcantara, Rommel M.R. Burbano, and Fabrício M. Tuji
|
| 824-824 |
|
| Transcriptomic analysis identifies four novel receptors potentially linking endometrial cancer with polycystic ovary syndrome and generates a transcriptomic atlas |
|
https://doi.org/10.18632/oncotarget.28513
Fatma Alqutami, Mahmood Hachim, Charlie Hodgman, and William Atiomo
|
| 825-835 |
|
| Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma |
|
https://doi.org/10.18632/oncotarget.28496
Michèle Welti, Phil F. Cheng, Joanna Mangana, Mitchell P. Levesque, Reinhard Dummer, and Laurence Imhof
|
| 836-836 |
|
| Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide |
|
https://doi.org/10.18632/oncotarget.28515
Alessandro Canella, Hector Cordero Nieves, Douglas W. Sborov, Luciano Cascione, Hanna S. Radomska, Emily Smith, Andrew Stiff, Jessica Consiglio, Enrico Caserta, Lara Rizzotto, Nicola Zanesi, Volinia Stefano, Balveen Kaur, Xiaokui Mo, John C. Byrd, Yvonne A. Efebera, Craig C. Hofmeister, and Flavia Pichiorri
|
| 837-838 |
|
| DISE, an ancient anti-cancer mechanism that senses mutational load in cancerous cells? |
|
https://doi.org/10.18632/oncotarget.28466
Monal Patel, and Marcus E. Peter
|
| 839-841 |
|
| Correction: Induction of phenotypic changes in HER2-postive breast cancer cells in vivo and in vitro |
|
https://doi.org/10.18632/oncotarget.28520
Anastasia Frank-Kamenetskii, Julia Mook, Meredith Reeves, Corinne A. Boulanger, Thomas J. Meyer, Lauren Ragle, H. Caroline Jordan, Gilbert H. Smith, and Brian W. Booth
|
| 842-842 |
|
| UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology |
|
https://doi.org/10.18632/oncotarget.28514
Meghan J. Price, Annee D. Nguyen, Jovita K. Byemerwa, Jasmine Flowers, César D. Baëta, and C. Rory Goodwin
|
| 843-857 |
|
| STAT3 as a biologically relevant target in H3K27M-mutant diffuse midline glioma |
|
https://doi.org/10.18632/oncotarget.28516
Jacob B. Anderson, Samantha M. Bouchal, Liang Zhang, and David J. Daniels
|
| 858-859 |
|
| Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity |
|
https://doi.org/10.18632/oncotarget.28518
Gulnur Zhunussova, Nazgul Omarbayeva, Dilyara Kaidarova, Saltanat Abdikerim, Natalya Mit, Ilya Kisselev, Kanagat Yergali, Aigul Zhunussova, Tatyana Goncharova, Aliya Abdrakhmanova, and Leyla Djansugurova
|
| 860-877 |
|
| Retraction: Serum amyloid a induces M2b-like macrophage polarization during liver inflammation |
|
https://doi.org/10.18632/oncotarget.28498
Yibin Wang, Haijun Huang, Renhua Sun, Bingyu Chen, Fang Han, Qian Li, Yin Ni, Xi Li, Jingquan Liu, Xiaozhou Mou, and Yuexing Tu
|
| 878-878 |
|
| Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells |
|
https://doi.org/10.18632/oncotarget.28517
Astha Lamichhane, Gary D. Luker, Seema Agarwal, and Hossein Tavana
|
| 879-889 |
|
| Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer |
|
https://doi.org/10.18632/oncotarget.28530
Devalingam Mahalingam, Salih Hanni, Anthony V. Serritella, Christos Fountzilas, Joel Michalek, Brian Hernandez, John Sarantopoulos, Paromitta Datta, Ofelia Romero, Sureshkumar Mulampurath Achutan Pillai, John Kuhn, Michael Pollak, and Ian M. Thompson
|
| 890-892 |
|
| Apoptotic cells may drive cell death in hair follicles during their regression cycle |
|
https://doi.org/10.18632/oncotarget.28529
Bradley D. Keister, Kailin R. Mesa, and Krastan B. Blagoev
|
| 893-899 |
|
| GLS2 shapes ferroptosis in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.28526
Sawako Suzuki, Divya Venkatesh, Tomoaki Tanaka, and Carol Prives
|
| 900-903 |
|
| The uncharted role of HER2 mutant alleles in breast cancer |
|
https://doi.org/10.18632/oncotarget.28489
Rashi Kalra, Bora Lim, Matthew J. Ellis, and Shyam M. Kavuri
|
| 904-907 |
|
| Correction: MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase |
|
https://doi.org/10.18632/oncotarget.28533
Recep Bayraktar, Martin Pichler, Pinar Kanlikilicer, Cristina Ivan, Emine Bayraktar, Nermin Kahraman, Burcu Aslan, Serpil Oguztuzun, Mustafa Ulasli, Ahmet Arslan, George Calin, Gabriel Lopez-Berestein, and Bulent Ozpolat
|
| 908-909 |
|
| FAAH inhibition ameliorates breast cancer in a murine model |
|
https://doi.org/10.18632/oncotarget.28534
Mallika Tripathy, Amy Bui, Jared Henderson, Jeffrey Sun, Christian Rutan Woods, Soumya Somani, Thao Doan, Anto Sam Crosslee Louis Sam Titus, and Chandra Mohan
|
| 910-918 |
|
| The double-edge sword of CRISPR application for in vivo studies |
|
https://doi.org/10.18632/oncotarget.28459
Martin K. Thomsen
|
| 919-920 |
|
| Risk factors for long-term arm morbidities following breast cancer treatments: A systematic review |
|
https://doi.org/10.18632/oncotarget.28539
Ifat Klein, Michael Friger, Merav Ben David, and Danit Shahar
|
| 921-942 |
|
| Retraction: Matrine alleviates lipopolysaccharide-induced intestinal inflammation and oxidative stress via CCR7 signal |
|
https://doi.org/10.18632/oncotarget.28119
Guojun Wu, Wenhong Zhou, Junfeng Zhao, Xiaohua Pan, Yongjie Sun, Hao Xu, Peng Shi, Chong Geng, Ling Gao, and Xingsong Tian
|
| 943-943 |
|
| Therapeutic potentials and challenges of cytostatic persister cancer cells |
|
https://doi.org/10.18632/oncotarget.28488
Paul Y. Kim, and Cheuk T. Leung
|
| 944-945 |
|
| Addendum: Nasal NK/T cell lymphoma presents with long-term nasal blockage and fever: a rare case report and literature review |
|
https://doi.org/10.18632/oncotarget.28285
Hai Zou, Ke-Hua Pan, Liang Wu, Hong-Ying Pan, Ya-Hui Ding, and Ming-Hua Zheng
|
| 946-946 |
|
| Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.28474
Alessia Roma, Lawrence D. Goodridge, and Paul A. Spagnuolo
|
| 947-948 |
|
| Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin |
|
https://doi.org/10.18632/oncotarget.28538
Carsten Springer, Jürgen Krauter, and Arne Trummer
|
| 949-956 |
|
| Osteopontin induces mitochondrial biogenesis in deadherent cancer cells |
|
https://doi.org/10.18632/oncotarget.28540
Gulimirerouzi Fnu, and Georg F. Weber
|
| 957-969 |
|
| Correction: Abnormal topological organization in white matter structural networks in survivors of acute lymphoblastic leukaemia with chemotherapy treatment |
|
https://doi.org/10.18632/oncotarget.28535
Liwei Zou, Lianzi Su, Rongmiao Qi, Fang Bao, Xianjing Fang, Longsheng Wang, Zhimin Zhai, Dan Li, and Suisheng Zheng
|
| 970-970 |
|
| Addendum: Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study |
|
https://doi.org/10.18632/oncotarget.28491
Ellery Altshuler, Raymond Richhart, William King, Mahmoud Aryan, Akash Mathavan, Akshay Mathavan, Keegan Hones, Daniel F. Leach III, Logan Pucci, Joshua Riklan, Pat Haley, Ilyas Sahin, Brian Ramnaraign, Sherise Rogers, Ibrahim Nassour, Steven Hughes, Thomas J. George, and Jesus Fabregas
|
| 971-971 |
|
| Melatonin and carcinogenesis in mice: the 50th anniversary of relationships |
|
https://doi.org/10.18632/oncotarget.28537
Vladimir N. Anisimov, and Alexey G. Golubev
|
| 972-976 |
|
| Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability |
|
https://doi.org/10.18632/oncotarget.28541
Flávia Dias Xavier, Danielle Leão Cordeiro de Farias, Abrahão Elias Hallack Neto, Glaciano Nogueira Ribeiro, Marco Aurelio Salvino de Araujo, Thiago Xavier Carneiro, and Otavio Cesar Carvalho Guimarães Baiocchi
|
| 977-994 |
|
| Therapeutically harnessing cancer stem cell-derived exosomes |
|
https://doi.org/10.18632/oncotarget.28542
Yong Teng
|
| 995-996 |
|
| The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies |
|
https://doi.org/10.18632/oncotarget.28543
Fusheng Zhou, Lili Tang, Siyuan Le, Mei Ge, Dragan Cicic, Fubo Xie, Jinmin Ren, Jiong Lan, and Qiang Lu
|
| 997-1008 |
|
| Transformation-associated recombination (TAR) cloning and its applications for gene function; genome architecture and evolution; biotechnology and biomedicine |
|
https://doi.org/10.18632/oncotarget.28546
Natalay Kouprina, and Vladimir Larionov
|
| 1009-1033 |
|
| One more step toward treatment of PARP inhibitor-resistant ovarian cancers |
|
https://doi.org/10.18632/oncotarget.28545
Upasana Ray, Prabhu Thirusangu, and Viji Shridhar
|
| 1034-1035 |
